The invention in this patent application relates to 1 H -indazole derivatives represented herein by formula 1. These compounds are inhibitors of hyperpolarization activated cyclic-nucleotide (HCN) modulated ion channel activity, with a selectivity for the inhibition of HCN1/HCN2 isoforms over the HCN4 isoform....
No actionable change — this is a patent application describing candidate molecules at a preclinical stage; no human trial data exist yet.
HCN channel inhibition represents a novel mechanistic target for tinnitus pharmacotherapy, a field with no FDA-approved drug to date.
- 01Patent application covers 1H-indazole derivative compounds targeting HCN ion channels.
- 02Proposed indications include tinnitus, pain, CNS disorders, and psychiatric conditions.
- 03HCN channels modulate neuronal excitability — dysregulation is implicated in tinnitus pathophysiology.
- 04No clinical or animal efficacy data are reported in this communication.
- 05Represents early-stage IP activity, not a clinical advance.
HCN ion channel inhibitors may be effective therapy for tinnitus.
press releaseunclear1H-indazole derivatives act as HCN ion channel inhibitors.
studypartially supported- PMID
- 42445009
- DOI
- 10.1021/acsmedchemlett.6c00320.
- Journal
- ACS Medicinal Chemistry Letters
- Publication type
- research_article
- Evidence level
- 5
- Population
- Not applicable — patent application; no human or animal subjects reported
- Intervention
- 1H-indazole derivative HCN ion channel inhibitors
Primary outcomes
Proposed therapeutic activity against tinnitus, pain, CNS and psychiatric disorders